Cargando…
Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
Anti-cancer activity can be improved by engineering immune cells to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens. Retroviral vector gene transfer strategies allow stable and durable transgene expression. Here, we used alpharetroviral vectors to modify NK-92 cell...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310147/ https://www.ncbi.nlm.nih.gov/pubmed/34372571 http://dx.doi.org/10.3390/v13071365 |
_version_ | 1783728690579898368 |
---|---|
author | Morgan, Michael A. Kloos, Arnold Lenz, Daniela Kattre, Nadine Nowak, Juliette Bentele, Marco Keisker, Maximilian Dahlke, Julia Zimmermann, Katharina Sauer, Martin Heuser, Michael Schambach, Axel |
author_facet | Morgan, Michael A. Kloos, Arnold Lenz, Daniela Kattre, Nadine Nowak, Juliette Bentele, Marco Keisker, Maximilian Dahlke, Julia Zimmermann, Katharina Sauer, Martin Heuser, Michael Schambach, Axel |
author_sort | Morgan, Michael A. |
collection | PubMed |
description | Anti-cancer activity can be improved by engineering immune cells to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens. Retroviral vector gene transfer strategies allow stable and durable transgene expression. Here, we used alpharetroviral vectors to modify NK-92 cells, a natural killer cell line, with a third-generation CAR designed to target the IL-3 receptor subunit alpha (CD123), which is strongly expressed on the surface of acute myeloid leukemia (AML) cells. Alpharetroviral vectors also contained a transgene cassette to allow constitutive expression of human IL-15 for increased NK cell persistence in vivo. The anti-AML activity of CAR-NK-92 cells was tested via in vitro cytotoxicity assays with the CD123(+) AML cell line KG-1a and in vivo in a patient-derived xenotransplantation CD123(+) AML model. Unmodified NK-92 cells or NK-92 cells modified with a truncated version of the CAR that lacked the signaling domain served as controls. Alpharetroviral vector-modified NK-92 cells stably expressed the transgenes and secreted IL-15. Anti-CD123-CAR-NK-92 cells exhibited enhanced anti-AML activity in vitro and in vivo as compared to control NK-92 cells. Our data (1) shows the importance of IL-15 expression for in vivo persistence of NK-92 cells, (2) supports continued investigation of anti-CD123-CAR-NK cells to target AML, and (3) points towards potential strategies to further improve CAR-NK anti-AML activity. |
format | Online Article Text |
id | pubmed-8310147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83101472021-07-25 Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 Morgan, Michael A. Kloos, Arnold Lenz, Daniela Kattre, Nadine Nowak, Juliette Bentele, Marco Keisker, Maximilian Dahlke, Julia Zimmermann, Katharina Sauer, Martin Heuser, Michael Schambach, Axel Viruses Article Anti-cancer activity can be improved by engineering immune cells to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens. Retroviral vector gene transfer strategies allow stable and durable transgene expression. Here, we used alpharetroviral vectors to modify NK-92 cells, a natural killer cell line, with a third-generation CAR designed to target the IL-3 receptor subunit alpha (CD123), which is strongly expressed on the surface of acute myeloid leukemia (AML) cells. Alpharetroviral vectors also contained a transgene cassette to allow constitutive expression of human IL-15 for increased NK cell persistence in vivo. The anti-AML activity of CAR-NK-92 cells was tested via in vitro cytotoxicity assays with the CD123(+) AML cell line KG-1a and in vivo in a patient-derived xenotransplantation CD123(+) AML model. Unmodified NK-92 cells or NK-92 cells modified with a truncated version of the CAR that lacked the signaling domain served as controls. Alpharetroviral vector-modified NK-92 cells stably expressed the transgenes and secreted IL-15. Anti-CD123-CAR-NK-92 cells exhibited enhanced anti-AML activity in vitro and in vivo as compared to control NK-92 cells. Our data (1) shows the importance of IL-15 expression for in vivo persistence of NK-92 cells, (2) supports continued investigation of anti-CD123-CAR-NK cells to target AML, and (3) points towards potential strategies to further improve CAR-NK anti-AML activity. MDPI 2021-07-14 /pmc/articles/PMC8310147/ /pubmed/34372571 http://dx.doi.org/10.3390/v13071365 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Morgan, Michael A. Kloos, Arnold Lenz, Daniela Kattre, Nadine Nowak, Juliette Bentele, Marco Keisker, Maximilian Dahlke, Julia Zimmermann, Katharina Sauer, Martin Heuser, Michael Schambach, Axel Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title_full | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title_fullStr | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title_full_unstemmed | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title_short | Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 |
title_sort | improved activity against acute myeloid leukemia with chimeric antigen receptor (car)-nk-92 cells designed to target cd123 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310147/ https://www.ncbi.nlm.nih.gov/pubmed/34372571 http://dx.doi.org/10.3390/v13071365 |
work_keys_str_mv | AT morganmichaela improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT kloosarnold improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT lenzdaniela improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT kattrenadine improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT nowakjuliette improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT bentelemarco improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT keiskermaximilian improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT dahlkejulia improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT zimmermannkatharina improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT sauermartin improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT heusermichael improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 AT schambachaxel improvedactivityagainstacutemyeloidleukemiawithchimericantigenreceptorcarnk92cellsdesignedtotargetcd123 |